Multifunctional dendritic polymers in nanomedicine: opportunities and
challenges by Khandare, Jayant et al.
 
This article was published as part of the 
Nanomedicine themed issue 
 
 
Guest editors Frank Caruso, Taeghwan Hyeon and Vincent Rotello 
 
 
Please take a look at the issue 7 2012 table of contents to 



















































View Article Online / Journal Homepage / Table of Contents for this issue
2824 Chem. Soc. Rev., 2012, 41, 2824–2848 This journal is c The Royal Society of Chemistry 2012
Cite this: Chem. Soc. Rev., 2012, 41, 2824–2848
Multifunctional dendritic polymers in nanomedicine: opportunities
and challengesw
Jayant Khandare,za Marcelo Caldero´n,zb Nilesh M. Dagiaa and Rainer Haag*b
Received 8th September 2011
DOI: 10.1039/c1cs15242d
Nanotechnology has resulted in materials that have greatly improved the eﬀectiveness of drug
delivery because of their ability to control matter on the nanoscale. Advanced forms of
nanomedicine have been synthesized for better pharmacokinetics to obtain higher eﬃcacy, less
systemic toxicity, and better targeting. These criteria have long been the goal in nanomedicine,
in particular, for systemic applications in oncological disorders. Now, the ‘‘holy grail’’
in nanomedicine is to design and synthesize new advanced macromolecular nanocarriers and to
translate them from lab to clinic. This review describes the current and future perspectives of
nanomedicine with particular emphasis on the clinical targets in cancer and inﬂammation.
The advanced forms of liposomes and polyethylene glycol (PEG) based nanocarriers, as well as
dendritic polymer conjugates will be discussed with particular attention paid to designs, synthetic
strategies, and chemical pathways. In this critical review, we also report on the current status and
perspective of dendritic polymer nanoconjugate platforms (e.g. polyamidoamine dendrimers and
dendritic polyglycerols) for cellular localization and targeting of speciﬁc tissues (192 references).
1 Introduction
Nanotechnology is a rapidly advancing, innovative ﬁeld of
science. It involves interdisciplinary research that is aimed
towards the production, characterization, development, and
application of ‘‘molecular’’ materials with sizes ranging
between 109 m (nanometre) and 106 m (micrometre).1,3
A speciﬁc example is the application of nanotechnological
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products for highly speciﬁc medical intervention at the macro-
molecular scale. The classical molecular bottom-up approach
(1–100 nm) will be joined by a top-down approach. More
recently, methods used to generate nanoscale structures and
nanostructured materials are deﬁned on the basis of either as
‘‘top-down’’ or ‘‘bottom-up’’. In the top-down approach,
lithographic methods have been utilized to pattern nanoscale
structures. While, in the bottom-up approach, interactions
between molecules or colloidal particles are utilized to assemble
the discrete nanoscale structures in two and three dimensions.4
Recently, many devices have been conceptualized to fabricate
with precision and to control the nanosize of materials using
the top-down approach. De Simone et al. have reported the
PRINTs process technology to obtain nanoscale control over
the bulk heterojunction device architecture.5 In this review we
focus on the bottom-up approach, especially on soft matter
polymeric systems as ‘‘nanotherapeutics’’.
Within the area of anticancer nanotherapeutics, it is antici-
pated that the nanotechnology based formulations will enhance
the eﬃciency of the free form of drugs by imparting targeting to
the desired organ/tissue/cell/cellular compartment and, concomi-
tantly, reducing the systemic toxicity of the drug. Thus, it is not
surprising that an emerging active area of academic and applied
research in oncology is to identify the molecular targets which
would facilitate the delivery of multifunctional nanosystems
consisting of (i) polymeric nanocarriers, (ii) a targeting moiety
possessing greater aﬃnity or recognition for the cellular receptors,
(iii) a therapeutic moiety, and/or (iv) an imaging probe. A parallel
burst of interest has occurred in the production and characteriza-
tion of new nanosystems, which require a highly interdisciplinary
research environment. Some critical questions that have risen are
whether the right nanosystems are being designed and evaluated?
Whichmaterials could be transformed into nanoforms (e.g. depots,
nanoparticles) with the right inherent traits and suitability for
Fig. 1 Multifunctional polymeric nanosystems under clinical consideration.
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nanocarrier systems? However, not enough polymer architectures
are being designed and critically evaluated to deliver the drugs at
the targeted site. To date, linear poly(ethylene glycol) (PEG),
poly(lactide-co-glycolide) (PLGA), polysaccharide based, and
amino acid based polymers have been successfully implicated,
particularly to deliver the bioactives through the systemic
circulation. More recently, advanced polymeric architectures such
as hyperbranched molecules have been introduced and are now
being evaluated for their safety and ability to deliver therapeutic
agents.
A growing volume of literature indicates that an array of
structurally diverse nanostructures of diﬀerent sizes (e.g. quantum
dots, nanoparticles, prodrug conjugates, nanospheres, nanotubes,
nanocrystals, nanogels, liposomes, micelles etc.) are being developed
for diagnostics or treatment related purposes (Fig. 1). Linear forms
of PEG, multifunctional linear polymers like HPMA, dendritic
polymers, and their conjugates are some of the nanostructural
architectures that have been widely characterized and studied.6–10
In this review we focus on the carriers and targeted conjugate forms
of nanomedicines (polymer–prodrug conjugates and polyglycerol
based nanogels). In particular, we discuss and compare the con-
jugation strategies of bioactives with PEG and dendritic polymers.
The application of these conjugates for combating oncologic and
auto-immune/inﬂammatory disorders (by virtue of their cellular
localization and targeting the pertinent tissue) is also described.
Towards the end, we delineate the current and future perspectives
of such nanomedicines in therapeutics.
1.1 Deﬁnitions
Nanocarrier. The term ‘‘nanocarrier’’ is used to describe
hybrid multifunctional systems with sizes typically ranging
between 1–200 nm which may deliver the bioactive agent at the
targeted site with improved therapeutic activity over the free
form of bioactive agent. To date, they are also involved in long
circulating liposomes, polymeric prodrug conjugates, polymeric
micelle, nano/microgels, and nanocomplexes.
Polymer therapeutics. The term ‘‘polymer therapeutics’’4–6
encompasses several diﬀerent classes of polymeric systems
including polymeric drugs, drug–polymer conjugates, polymeric
micelles covalently linked to drugs, multicomponent polyplexes
(including covalent unions), and prodrug–protein complexes.11–13
Nanomedicine. The term ‘‘nanomedicine’’,13,14 is used to
imply the application of nanotechnology (usually regarded
within the size range of 1–200 nm) in the design of systems and
devices that can facilitate better understanding, diagnosis,
and treatment of pathological diseases. Nanodiagnostics and
nanotheranostic technologies are other important ﬁelds of
nanomedicine.13,15
1.2 Biophysical requirements
The interface between nanomaterials and biological systems is
of great importance due to their associated toxicity and overall
safety. As a result, the biophysicochemical interactions at the
nano–bio interface can be thoroughly predicted due to the
relationship between structure and activity and properties such
as size, shape, surface chemistry, roughness, and surface
coatings.16
The in vivo biocompatibility of nanoparticles based on their
physical characteristics can be seen in a three-dimensional
phase diagram (Fig. 2).16 The qualitative biocompatibility
trends are revealed after screening around 130 nanoparticles
in vivo intended for therapeutic applications. The particle
variables that determine in vivo biocompatibility are size, zeta
potential, and dispersibility. The biocompatibility is shown
with red representing toxicity, blue the safety, and blue-green-
yellow intermediate levels of safety (in the same order). This
also reconﬁrms that the traits of cationic particles with high
surface reactivity would be more toxic (red hue) than the
larger hydrophobic or poorly dispersed particles. In addition,
they are rapidly and safely (blue hue) removed by the reticulo-
endothelial system (RES). Therefore nanoparticles with sizes over
10 nm need to be biodegradable for eﬀective clearance by kidney
or biliary tract (Fig. 2). Interestingly, the particles with the most
enhanced permeation and retention (EPR) in anticancer drug
delivery systems are average sized and have a neutral surface
charge.
More studies focused in this direction have been recently
done by the Haag group, wherein the structure–activity relation-
ship of dendritic polyglycerol (dPGs) derivatives is predominantly
disclosed.17,18 Interestingly, surface charge properties of diﬀerent
dPGs are highlighted in terms of surface functionalities and
compared with amine and hydroxyl terminated polyamidoamine
(PAMAM) dendrimers. Furthermore, the cell biocompatibility
studies demonstrated that the dPGs are as non-toxic as linear
PEG polymer or dextran.
Fig. 2 Physical characteristics of nanoparticles determined in terms of in vivo biocompatibility. Modiﬁed with permission from ref. 16, Copyright
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2 Current status of nanomedicines
The emerging ﬁeld of nanotherapeutics has already had multiple
success stories based on innovations related to covalent conjuga-
tion of polymers with drugs or proteins (Table 1). Although a
variety of nanotherapeutics have been conceptualized in the form
of drug delivery systems (liposomes, nanoparticles, micelles),
polyplexes (e.g. DNA–polycation complexes), polymeric
micelles, dendritic core–shell architectures as well as nanoparticle
depots, the clinical success of nanomedicine is best exempliﬁed by
the utilization of polymeric conjugates to eﬀectively deliver
therapeutically relevant drugs, peptides, proteins, and antibodies
(Fig. 3). Several polymers have been approved for use as a
conjugate for delivering bioactive agents in the form of nano-
therapeutics. However, poly(ethylene glycol) (PEG) remains the
polymer of choice for ‘‘clinical’’ prodrug conjugation. This
technology is now commonly referred to as ‘PEGylation’.10–12
The companies Nektar and Enzon have developed clinically
successful PEG based protein conjugates such as PEGylated
asparaginase (Oncospars), PEGylated bovine adenosine
deaminase (Adagens), PEGylated interferons, PEGylated
granulocyte colony stimulating factor, and PEGylated insulin.
Companies, such as Pﬁzer, Schering Plough, Roche, and Amgen,
have PEG-conjugates (PEGvisomant, PEG-intron, PEGasys, and
Neulasta) that have been clinically applied as nanotherapeutics
(Table 1). Besides the PEG-based technologies, several other
polymer conjugates are also being evaluated for their potential
to ameliorate the treatment of diﬀerent human diseases. Of note, a
conjugate of polystyrene-co-maleic acid and neocarzinostatin
(SMANCS;marketed byYamanouchi Pharmaceutical Company)
is being used to treat hepatocellular carcinoma. The cumulative
evidence from these clinical formulations has ﬁrmly established
that nanoconjugates improve the therapeutic value of bioactives
by any of the following approaches: (i) increasing the half-life of
poorly bioavailable molecules, (ii) reducing the immunogenicity,
(iii) decreasing the systemic toxicity, and (iv) exhibiting increased
stability over the free form of the bioactive.
2.1 Implications and rationale for eﬀective nanodelivery
systems
An advanced area of nanomedicine is based on the potential
utility of polymeric systems in the diagnosis and/or treatment
of cancer. Indeed, various classes of polymer–drug conjugates,
polymer–protein conjugates, nanoparticles, polymeric micelles,
and multicomponent polyplexes have been extensively studied
and some are routinely being used in clinical settings.19–22
Currently, a plethora of highly potent anti-cancer drugs are
available, but the selective targeting of these drugs to pertinent
sites still remains a challenging task. Several important consider-
ations are to be borne in mind when polymer–drug conjugates
are being sought to deliver and speciﬁcally target anti-cancer
drugs. These include the design of a stable covalent linkage
between the drug and polymer, to ensure the uptake of pro-drug
in tumor cells (e.g., via an endocytic route),12 improvement of the
‘‘pay load’’ and retention of drug within cancer cells, and
utilization of ligands (e.g., antibody, peptide, carbohydrate) to
increase the targetability of the polymer conjugate.23,24 The
above parameters are critical for the targeted delivery of not
only highly toxic small molecule anti-cancer drugs but also
Table 1 PEG, dendrimer, and other nanocarrier platforms (e.g., liposome, nanoparticles) in clinic
Nanomedicine Company Form Indication Delivery route
Pegasys, Peginteron Nektar Hoﬀmann-La Roche Linear PEG (40 kDa) conjugated




Wyeth Recombinant humanized IgG4,





Xyotax, Paclitaxel (37 wt%) Cell Therapeutics Poly L-glutamic acid (40 kDa) Non-small cell lung
cancer
i.v. or i.m.
Oncospar PEG Asparginase mPEG (5 kDa) Acute lymphocytic
leukemia
i.v. or i.m.
VivaGel Starpharma Holdings Dendrimer gel Vaginal microbicide for
prevention of HIV and
genital herpes
Vaginal gel
Aurimune (CYT-6091) CytImmune Sciences Colloidal gold nanoparticles
coupled to TNF and PEG-thiol
Solid tumors i.v.
Somavert Nektar Pﬁzer Pegvisomant (PEF-hGH) Acromegaly s.c.
















Abraxis Nanoparticles size Metastatic breast cancer i.v.
Doxil/Caelyx
(Doxorubicin HCl)
OrthoBiotech PEG stabilized liposome Ovarian cancer Kaposi’s
sarcoma
i.v.
DaunoXomes (Daunorubicin) Gilead Sciences Liposomal emulsion Advanced HIV-related
Kaposi’s sarcoma
i.v.
Certolizumab Cimzias UCB Inc. Pegylated form of antibody Crohn’s disease Subcutaneous
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macromolecular oncologic therapeutics encompassing peptides,
oligonucleotides, and antibodies.25,26
Although many nanodelivery systems have been adroitly
synthesized, each platform technology needs to be critically
evaluated in a speciﬁc therapeutic application prior to its being
labeled as ‘nanomedicine’. Because of the inherent cellular and
molecular complexities of myriad human diseases, this remains a
challenge. At the same time, this presents several opportunities.
In the past, many startup companies and research laboratories
have successfully introduced nanoplatforms. As a speciﬁc example,
Lupron depot is now routinely used for treating prostate and other
hormone dependent cancers.27 Another example is Mylotarg, a
nanomedicine platform consisting of antibody–drug conjugate,
which is prescribed for acute myeloid leukemia. Several other
nanoplatforms including Oncospar, PEGASYS, Neulasta, and
Somavert can now be deemed as nanomedicine technology
(see Table 1 for additional nanomedicines in clinic).
In general, only a fraction of macromolecular agents reach
their biological targets in vivo. Thus, to enhance the therapeutic
activity, it is vital to increase the intracellular penetration of drug-
bearing nanoconjugates which reach their biological target
in vivo.28 Typically, the cellular plasma membrane serves as a
barrier which occludes the transport of molecules based on the
molecular weight, size, polarity, and charge of the macromolecule.
Nanocarriers, by virtue of their internalization or shielding of anti-
cancer agents, genes, and proteins, can ‘‘break’’ this barrier, cross
into the cytoplasmic region, and increase the probability of
heightened therapeutic response. Notably, the internalization of
the nanocarriers into the cancer cells is achievedmost eﬃciently by
simple diﬀusion or receptor-mediated endocytosis.29 Interestingly,
several polymeric candidates, designed to augment the therapeutic
response of a drug, may not be biocompatible due to their
unsuitable polymeric architecture, higher surface charge, and
inappropriate molecular weight.17,20 Furthermore, the physico-
chemical characteristics (e.g., immune response, pH dependency
proﬁle, pKa) of the polymeric candidates may also limit their
potential use. Accordingly, these factors need to be considered
when developing a nanomedicine based platform. Thus, critical
determinants for nanodelivery systems include: (i) identiﬁcation of
speciﬁc molecular target(s), (ii) selection of suitable nanopolymer
candidate(s), (iii) design of the nanocomponent delivery system,
(iv) characterization of the nanoform, and (v) in vitro and in vivo
biological activity and pharmacological evaluation.
To date, several diﬀerent approaches (including the use of
membrane-permeable peptides such as Tat protein and non-
arginines) have been adopted to increase the intracellular uptake
of nanotherapeutics.30 As a speciﬁc example, cell penetrating
peptides have been attached onto liposomal carriers and micelles
which results in enhanced uptake of the polymeric carriers.31 The
augmented expression of cell-surface receptors—in particular of the
receptors which are molecular mediators of disease—could also be
exploited to increase the intracellular uptake of nanodelivery
systems. For example, in oncologic indications, the vascular
endothelial growth factor (VEGF) receptor, which is prominently
present on the surface of several tumor cells, has served as an
‘‘internalization-facilitator’’. VEGF plays a major role in tumor
initiated angiogenesis.32 Furthermore, the largest class of oncologic
drugs that block angiogenesis are the multi-targeted tyrosine kinase
inhibitors (TKIs) targeting the VEGF receptor (VEGFR).33 Anti-
vascular endothelial growth factor therapies and, in particular,
bevacizumab as monoclonal antibody against vascular endothelial
growth factor, have demonstrated antitumor eﬃcacy, although the
mechanism of action in the latter is not fully understood. In this
context, only a few vectors and molecular transporters show
immense potential for breakthrough therapy as they deliver the
drugs at intracellular locations after facilitation of their transport
across the biological barriers.26
2.2 Enhanced permeability and retention eﬀect (EPR) and
types of targeting
Water soluble polymers are now routinely used to prolong the
drug circulation and residence time within aﬀected cells,
enhance the solubility of drug, and reduce the systemic toxicity
of drug.29,34,35 Back in the 1980s, Maeda et al. and Jain
observed that covalent conjugates of water soluble polymers
with cytotoxic drugs were more eﬀectively targeted to the
tumor tissue than to its free form of cytotoxic drug.36 Maeda
described his ﬁnding using the term ‘‘enhanced permeability
and retention (EPR) eﬀect’’. The EPR eﬀect, which leads to an
increased ‘‘passive’’ accumulation of macromolecules in the
tumor tissue, is governed principally by the hyper permeability
of tumor vasculature. This hyper permeability allows selective
extravasation of macromolecules into the tumor and poor
lymphatic drainage and resultant increased retention of
macromolecules in the tumor (Fig. 4).37–41
In order to exploit the EPR eﬀect, due consideration needs
to be given to the size and other physicochemical traits of the
polymeric delivery system. The following examples will illustrate
this view point. Abraxanes and Doxils were two of the ﬁrst
nanocarriers to be approved by the FDA for cancer treatment.
Given their relatively large sizes (130 and 150 nm, respectively), it
is unlikely that these nanodepots will deeply penetrate into a
tumor mass.42 Therefore, the size of these nanocarriers needs to
be critically optimized.43 Indeed, in a recent study, Sisson et al.
demonstrated that the polyglycerol (PG) microgel particles with
















































This journal is c The Royal Society of Chemistry 2012 Chem. Soc. Rev., 2012, 41, 2824–2848 2829
diameters ranging between 25–50 nm are very eﬃciently and
non-disruptively uptaken by the cancer cells.44 These studies
highlight the importance of an ‘‘optimal’’ size for at least a
partially eﬃcient passive accumulation of polymeric delivery
systems in the disease/distressed tissues.6,7,45,46
Tumor invasion, metastasis, and resistance to chemotherapeutic
drugs as well as radiation are major obstacles for the successful
treatment of cancer.47 Some of these limitations can be overcome
by therapeutic strategies that increase the speciﬁcity and eﬃcacy
and, at the same time, reduce the toxicity of the anti-cancer drugs.
One of these approaches includes targeting the polymeric delivery
systems speciﬁcally to the cancer cells.
The targetability of polymeric forms of nanodelivery systems
to the cancer cells and tumor can be achieved by adopting one of
the following two approaches: (1) passive targeting and (2) active
targeting (Fig. 5).48
2.2.1 Passive targeting. In the passive targeting approach,
the localized delivery of a drug is achieved, due to environ-
mental conditions in tumors and/or tumor bearing organs.48
It is well recognized that, in comparison to the normal tissues,
tumor microvascular endothelium exhibits an enhanced leaki-
ness which results in markedly elevated permeability to macro-
molecules.48 Furthermore, the tumor tissue is characterized by
ineﬀective lymphatic drainage.36 The combination of the
above characteristics, along with the hypervascularization
evident in the tumor microenvironment, leads to an accumulation
of lowmolecular weight drugs coupled with highmolecular weight
nanocarriers in tumors. Thus, the aforementioned accumulation
of macromolecules in tumor tissues has the potential to
‘‘passively’’ deliver the chemotherapeutic agent to the tumor.
Notably, the existence of this predicted EPR eﬀect has been
experimentally conﬁrmed by many types of macromolecular anti-
cancer nanodelivery systems.49 Theoretically, any high molecular
weight water-soluble drug carrier, including water-soluble
polymers, liposomes, and polymeric drugs, should display passive
tumor targeting. However, the degree of accumulation of a
polymeric nanodelivery system in the tumor will be a function
of size, molecular weight, overall charge, and hydrophobic–
hydrophilic characteristics of the delivery system.17,20 Subsequent
to its accumulation in the tumor tissues, the macromolecular form
of a drug can act as a depot by slowly releasing the low molecular
weight active drug. The conjugation of therapeutic agents to the
polymeric nanocarriers could potentially aﬀord further beneﬁcial
eﬀects. For example, multi-component macromolecular pro-drug
delivery systems may inﬂuence the drug distribution in the body,
with enhanced bioavailability due to controlled and/or delayed
release (Fig. 5). Such pro-drug systems often demonstrate
reduced systemic toxicity in comparison to the free form of the
drug. One of the earliest studies involving macromolecular
carriers reported the utilization of DNA as a carrier for two
oncologic drugs: daunorubicin (DNR) and doxorubicin
(DOX).50 It has been clearly established that DNA has a limited
carrier ability due to potential genomic alterations.47 In follow-
up studies, the authors conjugated DNR to human serum
albumin (HAS) via degradable peptide spacers. This conjugate
showed a 200% increase in the life-span of mice inoculated with
L1210 leukemia cells.51 Later in 2005, paclitaxel was successfully
bound with human protein albumin (brand Abraxane) to deliver
a highly water insoluble drug in chemotherapy. This albumin
based nano formulation could eliminate the use of chemical
solvents (like Cremophor) causing a hypersensitivity reaction.
In an alternative approach of passive targeting, the molecular
conditions in an organ bearing a tumor and/or in tumor environ-
ment are exploited to facilitate the drug release from the nano-
delivery system.52 These conditionsmay include, but are not limited
to, a particular pH, and the existence of certain enzymes and/or
microﬂora in a speciﬁc organ or tumor. For example, drug delivery
to the colonmight be targeted by formulating tablets with a speciﬁc
coating that is destroyed in the colon by colon-speciﬁc pH and/or
colon-speciﬁc bacteria.53–55 An important limitation of this
approach is the targeting of the entire organ and not just the
tumor itself. This can potentially cause severe organ cytotoxicity,
Fig. 4 Schematic representation of the (A) EPR eﬀect and the further (B) cellular uptake mechanism.7,36,37
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unless the selective stimuli of the tumor itself (e.g. lower pH)
are utilized.
The third passive tumor targeting approach is based on a
direct local delivery of polymeric nanocarrier conjugated anti-
cancer agents directly into the tumor site.52 This delivery
technique has the obvious advantage of excluding drug delivery
from the systemic circulation. While topical delivery for some
tumors may be achieved by injection or surgical procedures,
other tumors, for instance, in lung cancers, are diﬃcult to access
for local drug delivery. To overcome this, several aerosolized
technologies have been developed to locally deliver anti-cancer
agents to the lung.56
All of the above ‘‘passive’’ approaches for targeting the
polymeric forms of nanodelivery systems can be utilized to
enhance a tumor-speciﬁc delivery of drugs. However, these
approaches are rarely used as the predominant methodologies
in current cancer therapies. The preferred and more routinely
employed technique involves an ‘active targeting’ of the polymeric
forms of nanodelivery systems.
2.2.2 Active targeting. An active tumor targeting of a
nanodelivery system is usually achieved by coupling a targeting
component on polymeric delivery system that provides prefer-
ential accumulation of the entire drug-delivery system or only of
the drug in an organ bearing a tumor, in the tumor itself, in
cancer cells, or in intracellular organelles of speciﬁc cancer cells.52
The active targeting approach is based on the interactions
between a ligand and its cognate receptor or between speciﬁc
biological pairs (e.g., avidin–biotin, antibody–antigen, sialic
acid–carbohydrate).57 In most cases, a targeting moiety in a
nanodelivery system is focused on the speciﬁc receptor or antigen
overexpressed in the plasma membrane or intracellular
membrane in tumor cells.
This type of targeting is only possible when speciﬁc molecular
receptors are present in malignant human tumor cells. For
example, cancer cells often overexpress speciﬁc tumor associated
antigens, carbohydrate epitopes, or growth factor receptors on
their cell surfaces.23,58,59 Incorporation of a biorecognizable
moiety into the polymer carrier structure aﬀords an actively
targeted nano drug-delivery system. So far, the potential targeting
moieties that have been explored include monoclonal antibodies,
polyclonal antibodies and their fragments, carbohydrates (galactose,
mannose), peptides/proteins (melanocyte stimulating hormone,
transferrin, lutenizing hormone-releasing hormone, growth factors),
glycolipids, vitamins, and other ligands.44,58,59 Using these targeting
moieties, active polymer–drug conjugates can be selectively trans-
ported into tumor tissues.
The concept of active tumor targeting has been illustrated
by several approaches (Fig. 5). Many of these studies have
utilized chemo-immunoconjugates wherein either a drug is
directly conjugated with a monoclonal antibody or a
drug–macromolecule conjugate is formed with a monoclonal
antibody using a polymeric carrier. For example, the anti-
cancer agent neocarzinostatin (NCS) has been conjugated with
a murine monoclonal IgG1 antibody against a human colon
cancer-associated cell-surface antigen. The NCS-monoclonal
antibody conjugate showed signiﬁcant suppression of tumor
growth in patients with colon and rectal carcinoma and lower
acute toxicity than with free NCS.60,61 In separate studies,
NCS has been covalently conjugated with TES-23, a highly
speciﬁc anti-tumor tissue endothelium-speciﬁc monoclonal
antibody.62,63 The TES-23-NCS conjugate induced tumor
hemorrhagic necrosis showed marked anti-tumor activity
against rat/mice KMT-17 ﬁbrosarcoma. Furthermore, mice
treated with this immunoconjugate exhibited improved survival
with no observable side eﬀects.
These and other observations clearly demonstrate that
active targeting enhances the overall accumulation of a polymeric
nanodelivery system by the cancer cells thereby increasing the
amount of the applied dose to actually penetrate the cancer cells.
This may in turn lead to a substantial increase in the cytotoxicity
of the drug and thus to a more eﬀective anticancer activity.
2.3 Cellular localization and imaging ability of nanocarriers
Polymeric carrier platform involving prodrug delivery system
(PDS) is likely to possess greater cellular entry and extracellular
interactions compared to its free counterpart(s). This can be
attributed, at least in part, to the supplementary characteristics of
the polymeric carrier system. Indeed, the nanocarriers exhibit
some of the critical features (e.g., size, solubility, and molecular
mass) required for a total PDS to facilitate the elicitation of
enhanced eﬃcacy. Furthermore, polymers (e.g. PEG) act as a
penetration enhancer and improve the cellular internalization of
a drug more than its free form.64
The plasma membrane has a dynamic structural functionality
that segregates the chemically distinct intracellular milieu
(the cytoplasm) from the extracellular environment by regulating
and coordinating the entry and exit of small and large molecules.65
For example, many small molecules, such as amino acids, sugars,
and ions, can traverse the plasmamembrane through the action of
integral membrane protein pumps or channels. In contrast, larger
macromolecules are carried into the cell through membrane
bound vesicles by the ‘‘invagination’’ process and/or the plasma
membrane process recognized as ‘‘endocytosis’’. This process of
endocytosis encompasses two distinct mechanistic features: (a)
phagocytosis (the uptake of large particles) and (b) pinocytosis
(the uptake of ﬂuid and solutes). Phagocytosis is an active and
highly regulated process which involves speciﬁc cell-surface
receptors and signalling cascades mediated by Rho-family
GTPases.63 Of note, phagocytosis occurs in specializedmammalian
cells. Pinocytosis, which occurs in all cells, can take place in any of
the following four forms: (i) macropinocytosis, (ii) clathrin-
mediated endocytosis (CME), (iii) caveolae mediated endocytosis,
and (iv) clathrin and caveolaein dependent endocytosis (Fig. 6).
Each of these aforementioned endocytic pathways is known to
aﬀect a number of molecular processes including signal transduc-
tion, spatial organization, cell migration, and polarity. Intriguingly,
the role of clathrin accessory proteins and the mechanisms that
regulate clathrin-independent endocytosis are being extensively
investigated.65–67 Nevertheless, it is well-established that each
pathway of endocytosis is regulated by the nature of the cargo
molecule and its receptor.
The aﬃnity of polymeric molecules with cells and the
consequent cellular dynamics are of special interest in drug
discovery research. It has been demonstrated that nanocarriers
in the interstitial space of healthy tissue and tumor tissue are
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that are critically dependent on the aﬃnity of the polymer for
the cell surface.34 Notably, most inert synthetic polymeric
carriers are known to be taken up by ﬂuid-phase pinocytosis.67
Once in the cell, these polymers are traﬃcked to late endo-
somes and lysosomes for their degradation. However, many
polymers do not exhibit degradation by the lysosomal
environment and instead get accumulated in vesicles within
the cell.67 Although not well understood, this accumulation
could be signiﬁcant and result in toxicity over a period of time.
Several groups have sought to elucidate the distribution and
cellular dynamics of targeted nanosystems. In particular,
Minko and colleagues have performed a series of elegant
studies to understand the kinetics, internalization, and colocalization
of labelled lutenizing hormone-releasing hormone (LHRH) nano-
carriers containing ﬂuorescent probes.23 It is well-documented that
LHRH receptor expression is substantially more pronounced in
cancerous ovarian tissue than in normal ovarian tissue.23 Con-
sequently, the LHRH peptide has been extensively used as a
targeting moiety to direct the entire conjugate speciﬁcally to cancer
cells and to enhance its penetration and intracellular uptake.23,68,69
In earlier studies, the cellular dynamics of LHRHpeptide and PEG
polymer as a targeting moiety and a delivery vehicle was shown
on human ovarian carcinoma cells expressing LHRH receptors
(Fig. 7).23,68,69 In subsequent studies, it was demonstrated that the
rhodamine labeled LHRH peptide accumulated predominantly in
the plasma membrane and part of the cellular cytoplasm adjacent
to the outer cellular membrane.23,68 In contrast, the FITC-labelled
PEG polymer can be equally distributed in the cellular cytoplasm
and nuclei.65
Among other physical attributes, the size of a polymeric
carrier plays a crucial role in the cellular uptake of a drug.70
Furthermore, depending on the size, polymer particles possess
diﬀerent velocities, diﬀusion characteristics, and adhesion
properties. In general, particles less than 200 nm are considered
optimal for intravascular applications due to their better circulation
half-life compared to larger particles.71,72 Overall, there are some
established rules of thumb with respect to particle internalization
into the cell: particles with diameters >1 mm are internalized by
phagocytosis and those with diameters between 0.2–1 mm are
internalized by endocytosis. Interestingly, two recent studies
reported that particles as large as 5 mm can be endocytosed through
receptor mediated endocytosis thereby heralding a new window to
targeted delivery to the vasculature.73–75
It is interesting to note that linear PEG polymers of varied
molecular weights internalize at diﬀerent time intervals.64 In
this important study, two labelled PEG polymers with molecular
masses of 3000 Da and 20000 Da were used (Fig. 8). Intensive
internalization of lower molecular mass polymer started within
20 min after the beginning of incubation (Fig. 8B). Forty-ﬁve
minutes after the beginning of the exposure, 3000 Da FITC-
labelled polymer was distributed almost homogeneously within
the cancer cell (Fig. 8C). Intensive ﬂuorescence, comparable with
ﬂuorescence in the medium, was observed both in the cellular
cytoplasm and nuclei. PEG polymer with a molecular mass of
3000 Da easily penetrated into cellular cytoplasm and nuclei.
However, the internalization of the PEG polymer with a molecular
mass of approximately 20000 Da occurred much slower than with
the smaller polymer. Indeed, signiﬁcant accumulation of the
polymer in the cellular cytoplasm occurred only after 2–4.5 h after
the addition of the polymer to the medium (Fig. 8E and F).64
In line with the afore mentioned imaging study, the Haag
group has recently observed a molecular mass and size dependent
cellular uptake of dendritic polyglycerols indicating a molecular
weight/size optimum around 200 kDa/12 nm.18 It is important to
note that the internalization of nanocarriers is not solely dependent
on the molecular mass or size of the polymer but is also inﬂuenced
Fig. 6 Mechanisms of cellular entry by phagocytosis (the uptake of large particles) and pinocytosis (the uptake of ﬂuid and solutes). The
endocytic pathways diﬀer with regard to the size of the endocytic vesicle, the nature of the cargo (ligands, receptors and lipids), and the mechanism
of vesicle formation.65
















































2832 Chem. Soc. Rev., 2012, 41, 2824–2848 This journal is c The Royal Society of Chemistry 2012
Fig. 8 Cellular internalization of PEG polymers is critically dependent on the molecular mass of the PEGylated polymer. Images of FITC-
labelled PEG-polymers (low and high-molecular mass polymers) internalized in living cells at 37 1C at diﬀerent time points after the exposure.
Reprinted with permission from ref. 64. Copyright 2007 American Chemical Society.
Fig. 9 LHRH peptide as a tumor-speciﬁc targeting moiety increased accumulation of diﬀerent delivery systems in mice tumors bearing xenografts
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by several other critical parameters. Recently, Saad et al. used an
imaging tool to elucidate the eﬀective contribution of the polymeric
architecture, composition, size, and molecular mass of nanocarriers
on the eﬃcacy of imaging and targetability for tumor-speciﬁc
receptors.2 The study inducted the inﬂuence of nanocarriers using
a linear PEG polymer, PAMAM dendrimer, and liposome in vitro
and in vivo. The nanocarriers delivered the anticancer drug (pacli-
taxel) and/or imaging agent (Cy5.5) with almost a similar eﬃciency
(Fig. 9). The studies in this direction quantitatively measured the
cellular internalization of nanoconjugates, which deﬁnitely imparts
new avenues in nanotherapeutics.
3 Application of nanomedicines in speciﬁc diseases
3.1 Cancer
A prime focus in nanomedicine has been to deliver anticancer
drugs without the toxicity and nontargetability associated with
the free form of a drug. In this regard it is important to note
that, extensive research conducted over several decades has led
to a better understanding of the biology of oncologic disorders. It
is now well-established that the indeﬁnite and uncontrollable
tumor cell proliferation and metastasis are characterized by
aberrant or hyperactive complex signaling cascades. Some of
the molecular components of key signaling pathways involved in
the progression and sustenance of tumors include PI3K/mTOR,
VEGF, CDK, HIF-1a, PDFG, KIT, EGFR, JAK-STAT, and
Ras-Raf-MEK-ERK.76,77 Each of these molecular mediators are
amenable to intervention (using small molecule inhibitors and/or
monoclonal antibodies) leading to a therapeutic response. For
example, NVP-BEZ235 is a PI3K/mTOR inhibitor,78 bevacizumab
is a recombinant human monoclonal antibody that targets
VEGF,79 P276 is a small molecule targeting CDK-4,80 imatinib
mesylate targets PDGFR81 and KIT, erlotinib is a EGFR tyrosine
kinase inhibitor,82 INCB18424 targets the JAK/STAT pathway,83
and U0126 interferes with the ERK-MEK pathway.84
Many of the drugs developed so far have considerably
increased the survival of cancer patients. Such drugs are used
as a ﬁrst line of therapy for cancer patients. However, the
majority of these drugs (including cancer chemotherapeutics
such as DOXO, vincristine, cyclophosphamide, topotecan,
and paclitaxel) are not targeted, i.e., the drugs not only alter
the tumor cell function but also aﬀect normal body cells
leading to a signiﬁcant number of side eﬀects.85 This has led
to the concept of selectively targeting the delivery of oncologic
drugs to tumor or cancer cells. The latter could be achieved
either via active targeting using ligand(s) or carrier(s) or by
passive targeting (e.g., EPR eﬀect) of drugs. Both these
approaches have been discussed earlier in this review. A
variety of polymeric approaches could be utilized to obtain
cancer ‘‘nanotherapeutics’’. These include polymeric conju-
gates, nanoparticles, polymeric micelles, and liposomes.
In this context, it is noteworthy that monoclonal antibodies
or antibody fragments have been used to achieve a degree of
speciﬁcity for the target tissue and a wide range of binding
aﬃnities.86 Some antibodies such as trastuzumab [anti-
ERBB2, Herceptin] or rituximab [anti-CD20 (B-cell surface
receptor), Rituxan] have intrinsic cytotoxicity because they
interfere with molecules that stimulate cell proliferation and
diﬀerentiation.87,88
3.2 Rheumatoid arthritis
Other disorders/diseases, where there is a critical focus on drug
delivery through nanomedicine, are inﬂammation and rheumatoid
arthritis (RA). RA is a chronic, inﬂammatory autoimmune
disease that results in progressive joint destruction and
increased mortality. It is a well-established fact that the pro-
inﬂammatory cytokine tumor necrosis factor-a (TNF-a) plays
a critical role in the pathogenesis of RA by orchestrating the
inﬂammatory/immune-response in the synovium.89 Accordingly,
inhibiting the production and/or biological activity of TNF-a is
considered a promising therapeutic approach. Indeed, clinically
approved therapies for treating active RA include biological
TNF-a inhibitors such as etanercept (Enbrel), inﬂiximAb
(Remicade), and adalimumAb (Humira).89 More recently, a
PEGylated Fab fragment of a humanized monoclonal antibody
directed against TNF-a (certolizumab, a polymer–protein conju-
gate) has been approved for treating RA patients.90 The pegylation
leads to improved half-life thereby providing certolizumab with a
greater opportunity to elicit robust and signiﬁcant reductions in the
pathological symptoms of RA in patients with active disease.
Although these biological agents are considered as the cornerstone
in the treatment of RA, their use has severe limitations (e.g.,
parenteral route of administration, high cost of therapy).91 As
such, extensive industrial and academic research is being carried
out towards ﬁnding orally active TNF-a inhibitors (and/or other
anti-arthritic agents) which would have the same eﬀect as biological
agents but without the undesirable side eﬀects.92 The possible
targeting approaches in RA have been listed in Fig. 10.
A large number of studies have investigated the role of
various signal transduction pathways in the induced produc-
tion of TNF-a. These studies led to the identiﬁcation of p38
MAP kinase and PDE4D as attractive therapeutic targets for
alleviating RA by inhibiting TNF-a production. The promise
of p38 MAP kinase inhibitors and PDE4D inhibitors has been
evaluated in multiple clinical trials. Much to the disappoint-
ment of industry these clinical trials have failed.93 In order to
attain ‘‘eﬀective’’ drug concentrations in aﬀected joint tissues,
high doses of aforementioned inhibitors were administered to
patients which led to signiﬁcant adverse eﬀects (hepatotoxicity
with p38 MAPK inhibitors)93 and nausea and emesis with
PDE4D inhibitors.94 With the objective of reducing the side
eﬀects, the dose of PDE4D inhibitors was reduced but, in these
studies, lower doses of PDE4D inhibitors failed to elicit a
therapeutic response.94 Given this, polymeric chemistry approaches,
which speciﬁcally target these agents to aﬀected joints, can be
investigated with the hope of realizing the potential of these small
molecule inhibitors. An attractive strategy to target these inhibitors
to the rheumatic joint is to exploit the acidic microenvironment of
the synovial joint. The pH of the synovial ﬂuid from joints of RA
patients, which is reported to be as low as 6.0, correlates inversely
with the disease severity.95
Wang et al. have developed a novel water-soluble,
N-(2-hydroxypropyl) methacrylamide (HPMA) based polymeric
delivery system that selectively delivers dexamethasone (in a pH
sensitive manner) to inﬂamed joints of arthritic rats.92 In an
experimental model of arthritis, the polymeric dexamethasone–
HPMA conjugate aﬀorded superior and longer lasting anti-
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preservation, compared to free dexamethasone.92 The proof-
of-principle ‘‘polymer-chemistry’’ studies for p38 MAPK
inhibitors have been performed in the settings of acute myo-
cardial infarction.96 Sy et al. have demonstrated that micro-
spheres formulated from the polymer, poly(cyclohexane-1,4-diyl
acetone dimethylene ketal) (PCADK), which encapsulate the p38
MAPK inhibitor SB239063, can markedly improve the treatment
of acute myocardial infarction.96 Analogous polymeric-drug con-
jugate delivery systems could be adopted with promising p38
MAPK inhibitors and/or PDE4D inhibitors to achieve a sustained
therapeutic response in RA. Given that an acid azabisphosphonic-
capped, phosphorus-containing dendrimer elicits immunosuppres-
sive responses onmonocytes (a cardinal immune cell in pathology of
RA), a ‘‘dual-therapeutic response’’ strategy would be to tag these
promising p38MAPK/PDE4D inhibitors onto immunosuppression
eliciting dendrimers.97 Furthermore, as shown by Chandrasekar
et al. PEG conjugates of anionic poly(amidoamine) dendrimers
can be targeted using folate receptor (which is overexpressed on
the activated—but not quiescent—macrophages in both animals
model and human patients with naturally occurringRA) as an active
targeting moiety.98 In the context of harnessing the potential of
PDE4D inhibitors, it is noteworthy that ‘‘dual-complementary’’
polymeric nanocarrier approaches could be adopted which not only
target their delivery to the aﬀected rheumatic joint but also reduce
their systemic concentrations (which would lead to diminished side
eﬀects).
Besides TNF-a inhibitors, the standard therapy for RA consists
of disease-modifying anti-rheumatic drugs (DMARDs) such as
methotrexate. An important limitation of methotrexate (MTX)
therapy is that a meaningful protective response is observed only
after several weeks of therapy. In one such study by Homma et al.
MTX was conjugated to hyaluronic acid (HA) using a PEG13
linker.99 This MTX-HA conjugate consisted of MTX bonded
through a- or g-carboxylic acid, cleavable by enzymes; a peptide
chain recognized and cleaved by intracellular enzymes; a pegylated
linker to avoid the steric hindrance of HA against the approach of
enzymes and HA modiﬁed through its carboxylic acid.99 This
MTX-HA conjugate showed anti-proliferative eﬀects on human
synovial cells stimulated by using TNF-a. Moreover, it inhibited
knee swelling in an antigen-induced monoarthritis rat model.99
Besides the aforementioned therapeutic strategies, an alter-
native approach to achieve a therapeutic response in RA is to
modulate the aberrant leukocyte-synovial microvascular endo-
thelial cell adhesion.100 The leukocyte-endothelial cell adhesion is
mediated by speciﬁc cell adhesion molecules expressed on the
endothelium (e.g., E-selectin, P-selectin, VCAM-1) and their
cognate ligands on the leukocytes (e.g., sLeX, PSGL-1, L-selectin,
VLA-4). It is anticipated that therapeutics, which interfere with
the expression and/or functionality of these cell-adhesion molecules,
will attenuate the inﬂammatory cellular inﬁltrate in the synovium
thereby providing a therapeutic response. Polymeric chemistry
methodologies have been employed to exploit the promise of this
alternative approach. For example, Ali et al. have demonstrated that
multivalent presentation of sLeX-mimetics on a polylysine backbone
imparts anB30-fold improvement in inhibition of in vivo E-selectin
dependent leukocyte rolling.101Haag et al. have synthesized dendritic
polyglycerol sulfates (dPGS) that simultaneously antagonize
L-selectin on leukocytes and P-selectin on inﬂamed vascular
endothelium thereby reducing leukocyte extravasation.102 The
extent of L-selectin inhibition is dependent on the core size and
degree of sulfation of dPGS core.102 Most importantly, imaging
studies have revealed that dPGS targets and accumulates at the
site of inﬂammation (see below). Clearly, future studies aimed
towards evaluating the potential of the polymeric scaﬀolds amelio-
rating experimental arthritis are warranted. In this context, it
is noteworthy that Chauhan et al. have demonstrated anti-
inﬂammatory eﬃcacy of naked, unmodiﬁed poly(amidoamine)
(PAMAM) dendrimers bearing simple surface functionality
(e.g., –NH2, –OH, etc.) in rat adjuvant-induced arthritis.
103
The heightened expression of adhesion molecules on synovial
microvascular endothelium provides an opportunity for site
speciﬁc delivery of anti-rheumatic drugs. For example, a targeted
drug delivery scheme could be employed wherein anti-rheumatic
drugs are incorporated into drug carriers that bear a ligand for a
selectively expressed endothelial cell adhesion molecule (e.g.,
E-selectin or VCAM-1). Ideally, once administered, the carriers
would selectively bind to endothelium within inﬂamed synovial
tissue via the ligand-ECAM chemistry and not bind to other
segments of the endothelium or other tissue. In separate studies,
it has been demonstrated that HPMA copolymer-doxorubicin
conjugated displaying a high-aﬃnity E-selectin binding peptide104
or PAMAM dendrimers conjugated with an E-selectin anti-
body105 can be targeted to human endothelial cells. Analogous
polymer-encapsulated drug (e.g., PEG-PLA biodegradable
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particles encapsulating MTX) or polymer–drug conjugate
approaches (e.g., HPMA–copolymer conjugated with methotrexate
instead of doxorubicin) could be adopted to achieve the ‘‘synovium-
speciﬁc’’ delivery of anti-rheumatic drugs with the objective of
achieving a meaningful therapeutic response with diminished side
eﬀects.
4 Structural aspects of nanoconjugates
Nanoforms of polymeric prodrugs have been extensively used
to deliver drugs and other biomolecules. The process involves
synthetically coupling the biological active component with a
polymer carrier to form a unique molecule which possesses
collective property or its individual characteristic. Jatzkewitz
utilized a prodrug of peptamin-polyvinylpyrrolidone (PVP) as
a means of improving the eﬃcacy of the drug as early as
1955.106 Unfortunately, for the next couple of decades the
implications of prodrugs in therapeutics were not signiﬁcantly
noted. Since Ringsdorf was the ﬁrst to propose a rational
model for pharmacologically active polymers, he has been
often considered the pioneer of prodrug research.20 The
prodrug model typically consists of multiple components
including (i) a polymer as a carrier, (ii) a drug, peptide or
protein as a biological active component, (iii) a spacer mole-
cule for conjugation chemistry, and achieving cellular hydro-
lysis, and (iv) an optional imaging or targeting moiety.
Most of the state-of-the-art nanoconjugates possess a degrad-
able bond to release the drug at the site of action per the
pH gradient.107,108 The selection of the pro-drug components is
very crucial for designing the conjugates that can achieve mole-
cular targeting. The following properties of drug candidates
make them suitable for translation into a polymeric prodrug
from (i) chemical functionality for conjugation, (ii) low aqueous
solubility, (iii) instability at varied physiological pHs, (iv) higher
systemic toxicity, and (v) lower cellular entry.
Linking of a polymer to the drug is a ﬁrst key step in regulating
the biological activity of drug and for supporting a trigger for
activation of the macromolecular prodrug.20 Prodrug conjugates
have varied chemical linkages which are susceptible to neutral
pH (e.g. ester, hydrazone linkages), acid catalyzed cleavage
(e.g. cis aconityl groups), and their tendency to cleave by exposure
to the targeted enzyme such as cathepsins or esterase. Several
PEGylated enzymes (adenosine deaminase, L-asparaginase) and
cytokines (including interferon a and G-CSF) are routinely used
in therapeutics. PEG-modiﬁed adenosine deaminase (ADAGENs)
and PEG-L-asparaginase (ONCASPARs) were the ﬁrst PEG
modiﬁed enzymes to be on the market in early 1990s. In general
multifunctional biocompatible polymers are required as eﬃcient
nanocarriers that fulﬁl the above mentioned characteristics.
4.1 Multicomponent PEG conjugates for cancer targeting
PEGylation methodology can be utilized to maximize the
‘tumor cell-death eﬀect’ of oncologic drugs. In this approach,
the PEGylated oncologic drugs are targeted to cancer cells at
speciﬁc tumor sites by using targeting moieties (e.g., folic acid,
LHRH, antibodies).48,49 This multitargeting approach was
demonstrated by Dharap et al. by using a combination of
PEGylated camptothecin (CPT) and two diﬀerent targeting
agents LHRH and BCL2 homology 3 (BH3) peptide.69 The
authors utilized the LHRH peptide as a targeting moiety to
recognize extra-cellular LHRH receptors, which are distinctly
over-expressed in several cancer cells. Similarly, the BH3
peptide was utilized to target the intracellular machinery
critically controlling apoptosis to enhance the anticancer
activity of CPT.69 CPT was chemically conjugated to Boc-Cys
(Trt) amino acid to form a biodegradable ester bond with the
hydroxyl group. The resultant prodrug conjugate (CPT-cysteine
ester) had two potential, orthogonal conjugation sites: the amino
group and the thiol group (Fig. 11).
Facile chemical routes have been adapted to conjugate the
anticancer drugs with bifunctional PEG polymers. Furthermore,
the addition of other bioactive agents is critical for delivering
targeted multicomponent systems (Fig. 11). The eﬃcacy of the
prodrug conjugates was studied by cytotoxicity, gene expression
analysis, and apoptosis induction in human ovarian cancer
cells.69 PEG-CPT nanoconjugates elicited a higher cytotoxicity
and apoptosis induction than free CPT. Furthermore, targeting
using the BH3 peptide or LHRH peptide resulted in a better
eﬃcacy of non-targeted CPT-PEG conjugate.69 These ﬁndings
demonstrated that the simultaneous targeting and suppression of
Fig. 11 (a) Synthetic scheme for CPT-PEG-BH3 nanoconjugate. CPT was ﬁrst coupled to an amino acid via a biodegradable ester bond to the
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cellular anti-apoptotic defense substantially increased the anti-
cancer activity of CPT. However, a major drawback of bifunc-
tional PEGs is the poor drug loading, therefore multifunctional
polymers, especially dendritic nanocarriers, are of great interest
as polymeric scaﬀolds.
4.2 Dendritic polymers as nanocarriers
In the early 1980s, polymer science research introduced versatile
nanosized dendritic polymers, named after the Greek word
‘dendron’ for tree, which are macromolecules that can be
chemically designed and synthesized to possess precise structural
characteristics including a branch on branch, tree-like architec-
ture.109,110 Dendritic polymers can be classiﬁed as: (a) perfect
dendrimers, (b) dendrons, (c) dendronized polymers, and (d)
hyperbranched polymers. Perfect dendrons and dendrimers are
unique nanosystems because they can be expected to achieve
monodispersity (PDI E 1.0), nanometre dimensions (1–10 nm),
low viscosity, multiple functionality at the terminal groups, high
solubility, and biocompatibility. Hyperbranched and dendro-
nized polymers have broadened the nanosize range of dimensions
up to micrometre scale (PDI Z 1.1), with the concomitant
increase in the ﬁeld of applications.
In last 10 years extensive work has been published on dendritic
nanostructures and their conjugation strategies to deliver active
agents e.g. MTX, CPT, paclitaxel, cisplatin, etc.111,112 Addition-
ally, they have been used to evaluate their potential in tumor cell
speciﬁcity and targetability using folate residues, antibodies, and
hormones.7,113,114 These versatile polymers are synthesized from
monomeric units with new branches being added in steps until a
uniform tree-like structure is formed. A comparison of dendrimer
and linear polymer features shows that the dendritic polymer
architecture is advantageous for many delivery applications.115–121
For example, the deﬁned multivalency of dendrimers can be used
to encapsulate or conjugate similar or diﬀerent drug molecules
while adding on targeting, imaging probes, and/or solubilizing
modalities on the same construct in a controlled fashion.
In addition, their low polydispersity should provide a more
reproducible pharmacokinetic behavior than in linear polymers.
Furthermore, the more globular shape of dendrimers, as opposed
to the random coil structure of most linear polymers, could aﬀect
their biological properties and thus lead to the discovery of
interesting eﬀects due to their macromolecular architecture.122
In particular, the synergy between their multifunctionality
and size on the nanoscale enables a chemical ‘‘smartness’’
along their molecular scaﬀold that achieves environmentally
sensitive modalities. Therefore these functional materials can
be expected to revolutionize the existing therapeutic practice.
Dendritic molecules (Fig. 12), such as polyamidoamine
(PAMAM),123–125 poly(propylene imine),126 polyaryl ethers,127
polylysine,128 polyester,129,130 polyamide131 polyglycerol
(PG),132,133 and triazine dendrimers,134 have been introduced for
biomedical applications to amplify or multiply molecularly patho-
pharmacological eﬀects and have already shown a promising
higher eﬃcacy in the polymer therapeutics ﬁeld.135
4.3 Dendritic nanostructures as targeted drug delivery systems
Among the many special structural features of dendritic
nanostructures, the high density of functional groups is parti-
cularly interesting for the design of targeted drug–polymer
conjugates. The surface decoration of dendritic nanostructures
with solubilizing agents and targeting moieties together with
the inherent charge proﬁle of the dendritic polymer, confer
structural beneﬁts with consequences in a faster cellular entry,
reduced macrophage uptake, targeting, and easier passage
across biological barriers by trancytosis.112
In addition, their branched nature provides a better in vivo
application proﬁle than their linear polymeric analogs. For
instance, for polymers with similar MW and chemistry, increasing
the number of branches or arms increases the blood circulation
half-life. A systematic study with a library of PEGylated polyester
‘‘bow-tie’’ dendrimers (Fig. 13) established the relationship
between branching and blood circulation time.136,137 For a series
Fig. 12 Examples of dendritic scaﬀolds commonly used in drug delivery applications. (A) poly(propylene imine), (B) polyamidoamine,
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of bow-ties with equivalent MW (B40 kDa), there was an
increase in t1/2, from 1.4  0.4 h for the two-arm dendrimer,
essentially a linear polymer, to 26  6 h for the four-arm
dendrimer, and ﬁnally to 31  2 h for the eight-arm dendrimer.
Corresponding biodistribution studies in healthy mice showed no
signiﬁcant variation in tissue uptake among the three polymers
and decreased polymer excreted in the urine with increased
branching. This polymer drug carrier studied in C26 colon tumor
mice showed long blood circulation times and remarkable eﬃcacy
in delivering the chemotherapeutic drug doxorubicin to
tumors.136,137
PAMAM dendrimers, which are commercially available,
are being highly investigated for their biomedical applicability.
The practicability of PAMAM dendrimers for cancer treat-
ment is under critical investigation, as these nanocarriers serve
in the delivery of targeted drug components, therapeutic
agents, and imaging agents.138,139 Their characteristic non-
toxicity in biological systems makes them much more biocom-
patible than many other materials currently researched for use
as controlled, chemotherapeutic drug delivery systems.125
However, the possibility of retro-Michael addition limits their
shelf-life under ambient conditions.
Targeted dendritic anticancer prodrug conjugates of PAMAM
dendrimers have been successfully synthesized by using either a
multistep or one-pot approach, and targeting modalities like
antibodies, folic acid, biotin, peptides (RGD, LHRH, etc.), etc.
The internalization of dendritic nanocarriers by cancer cells is
much more eﬃcient than the penetration of free low molecular
weight drugs or non-targeted drug delivery system (DDS) by a
simple diﬀusion or endocytosis, respectively. Switching these
mechanisms substantially enhances intracellular internalization
and the anticancer eﬃcacy of the delivered drug and other active
components of DDS.140 This was demonstrated by using the
lutenizing hormone-releasing hormone (LHRH) peptide as a
tumor targeting moiety to receptors that are overexpressed in
the plasma membrane of many types of cancer cells. This is
advantageous for two reasons. First, in contrast to non-targeted
dendrimer-based DDS that accumulates almost equally in a
tumor, liver, and kidney, peptide used as a targeting ligand are
able to subject the entire nanocarrier system speciﬁcally to the
tumor and thus simultaneously prevent its accumulation in
healthy tissues. Secondly, the LHRH peptide enforced the inter-
nalization of DDS by cancer cells.
Majoros et al. reported conjugation of ﬂuorescein isothio-
cyanate (FITC), folic acid (FA), and methotrexate (MTX) to
G5 PAMAM dendrimer.116 Typically, FA belongs to the
vitamin B family and is important in cell division, since it
participates in the biosynthesis of nucleotide bases. While folic
acid receptors (FR) are membrane bound receptors and could
be targeted using FA as a ligand, it has been noted that the
expression of FR in normal tissues is low and restricted to
various epithelial cells, such as placenta, choroid plexus, lungs,
thyroid, and kidneys.141,142 Moreover, the FRs are overexpressed
in many epithelial cancer cells, such as breast, ovary, lung, kidney,
head and neck, brain, and myeloid cancers.143,144 The dendritic
device synthesized was targeted to overexpressed membrane
associated folate receptors with FA which induced cellular
cytotoxicity.
A novel ‘‘one pot’’ method for targeted delivery consisting of
generation 5 (G5) polyamidoamine (PAMAM) dendrimer, folic
acid (FA), and methotrexate (MTX) was reported.59 The ratio of
FA versus MTX conjugated to the dendrimer was tuned to
achieve the desired therapeutic eﬀect. In vitro studies performed
on FA receptor-expressing KB cells showed that the conjugate
has a similar aﬃnity and cytotoxic potency to G5-FA-MTX
synthesized using the traditional multiple-step approach.
A partially acetylated generation 5 (G5) polyamidoamine
(PAMAM) dendrimer was conjugated with the targeting
moiety biotin and the imaging moiety ﬂuoresceinisothiocyanate
(FITC). The bifunctional conjugate (dendrimer–biotin–FITC)
exhibited much higher cellular uptake into HeLa cells than the
conjugate without biotin. The results indicated that the biocom-
patible biotin–dendrimer conjugate might be a promising nano-
platform for cancer therapy and cancer diagnosis.
The Baker group has reported the use of Fibroblast Growth
Factor Receptor (FGFR), which is overexpressed in a wide
variety of tumors, as an active targeting fragment to be used in
cancer, wound healing, and in angiogenesis. Puriﬁed recombinant
FGF-1 was coupled to a G5 PAMAM dendrimer. The speciﬁc
binding and internalization of this conjugate labelled with FITC
was investigated by ﬂow cytometry and confocal microscopic
analysis in cell lines expressing FGFR. While the binding and
uptake of FGF-conjugated dendrimers was completely blocked
by excess nonconjugated FGF-1, confocal microscopic analysis
showed cytosolic as well as nuclear localization.145
It should be noted that the ratio of drugs conjugated per
nanocarrier has largely not been realistically achieved with a high
payload of drug or targeting moieties. This is particularly true for
dendritic architectures for the following reasons: (a) nanosized
radius of gyration (Rh), (b) higher steric hindrance exhibited by
the biomolecule as well as at the peripheral functional groups of
the dendrimer, (c) low reactivity of terminal functional groups for
chemical conjugation with biocomponent, and (d) crowding eﬀect
of reactive end groups in dendrimers. In one attempt to overcome
these issues, a high payload, averaging 50 ibuprofen molecules
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were conjugated per mole of poly(amidoamine) PAMAM G4
hydroxyl-terminal dendrimers.146 By decreasing the steric hindrance
and increasing the reactivity of a drug, as many as 12 methylpredni-
solone (MP) molecules were conjugated to a PAMAM G4
hydroxyl-terminated dendrimer. The spacer molecule glutaric acid
(GA) was coupled to MP to enhance the reactivity of the drug. The
resulting MP–GA–COOH moiety was further conjugated with a
hydroxylterminal dendrimer using DCC as a coupling agent.146 The
conjugate demonstrated comparable therapeutic activity to the free
drug, even over short intervals of time.
In contrast, other forms of dendrimers could be eﬃciently
used to deliver siRNA and nuclear components. It was
eﬀectively demonstrated that non-quaternized dendrimers often
form microtubule like structures with non-covered and non-
protected siRNA (Fig. 14A and B).140 Secondly, surface modiﬁca-
tion with charge neutral groups (acetylation or hydroxylation)
leads to the low cytotoxicity of empty dendrimers and enhanced
internalization of the entire DDS by cancer cells (Fig. 14C andD).
The synthesis of several DDS based on such dendrimers provides
experimental data that support the advantages of this approach to
complex multifunctional tumor targeted pro-apoptotic delivery
systems.
In response to the need of nanodelivery vehicles, a future
perspective is to control the properties and function of polymeric
carriers by designing well-deﬁned molecular architectures, to
impart biocompatibility, and to develop chemical versatility.
Dendrimers are an eﬃcient mean for the delivery of such traits to
multiple drugs, to ligands, at the sites of contact using a single
molecule. However, there is further need to design and evaluate these
‘dendritic nanocarriers’ for their in vivo toxicity, biodegradability,
cellular uptake, release, hemolytic eﬀect, and bio-interactions. In
particular, issues related to the conjugation of hydrophobic agents
on the surface of dendrimers (loss of homogeneity, steric hindrance,
conformational changes, high surface charge, etc.) should be over-
come. The development of a targeted nanocarrier system for
optimum eﬃcacy remains elusive and therefore needs to be designed
experimentally on a case to case basis.
5 Dendritic polyglycerol as a new platform for
nanomedicine
Dendritic polyglycerols (dPGs) are characterized by tunable
end group functionalities, deﬁned topological 3D architecture,
and inertness to non-speciﬁc interactions with biological
Fig. 14 Synthesis and evaluation of surface modiﬁed (A) and surface modiﬁed and internally quaternized (B) dendrimers. (C) Cytotoxicity of a
traditional (PAMAM–NH2) and novel surface modiﬁed (PAMAM–NHAc) dendrimers. (D) Cellular internalization of free siRNA, and
dendrimer–siRNA complexes with a traditional (PAMAM–NH2) and internally cationic and surface modiﬁed (QPAMAM-NHAc) dendrimers
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environments. dPGs present a novel platform for next generation
biomaterials.1,7,147 Multiple approaches to design diﬀerent PG
architectures have been reported, which oﬀer a great variety in
the degree of branching, size, surface topology, and chemical
properties in general. Along with the synthesis of hyperbranched
PG, fabrication routes to perfect dendrimers, dendrons, micro-
gels, and nanogels have also been reported over the last decade
(Fig. 15). A systematic library of PG architectures with varying
properties was synthesized using a careful selection of starting
materials through an economic synthetic route that provided an
option to perform post modiﬁcation on the PG scaﬀold.148
Since dPGs are synthesized in a controlled manner to obtain
deﬁnite molecular weight and narrow molecular polydispersity,
they have been extensively evaluated for a variety of biomedical
applications.1,115,149 Several studies have demonstrated the bio-
compatibility of dendritic PGs and a potentially safe proﬁle for
in vitro and in vivo applications. In preliminary cell culture
experiments, hyperbranched PG with a molecular weight of
5 kDa showed absolutely no toxicity on the cellular level.150
Brooks et al. reported several studies including a comprehensive
analysis of PGs in a broad MW distribution and with diﬀerent
compositions.151–154 Both linear and hyperbranched PGs were
reported to have a similar or even better biocompatibility proﬁle
than PEG with MW ranging from 4.2 kDa to 670 kDa. In vivo
studies conducted on mice revealed no sign of toxicity after i.v.
injection of the dose up to 1 g kg1. Although the biocompati-
bility of polymers in general is a function of molecular weight, no
MW dependent toxicity was found up to 540 kDa for dendritic
PG architectures. Dendritic PGs exhibit a plasma half-life of
32 hours (106 kDa) in mice for lower molecular weight polymer,
whereas it can be as high asB57 hours for high molecular weight
PGs (540 kDa).154 Currently, hyperbranched PGs are considered
as new delivery enhancers for many bio-actives which could
substantially increase the internalization of active components
speciﬁcally into targeted cells to enhance the speciﬁc activity of
the whole drug delivery system and thereby decrease the adverse
side eﬀects.155,156 Recently we demonstrated that chemically
post-modiﬁed hyperbranched polyglycerol presented suﬃciently
low zeta potentials, lower interactions with serum albumin,
enhanced cellular uptake, and high cellular viability on human
hematopoietic cell line U-937.17 Hyperbranched polyglycerol
scaﬀolds with average MW between 10 kDa and 20 kDa, and
surface functionalities suitable for further drug encapsulation or
conjugation were assayed for biocompatibility compared to
linear PEG polymer or dextran, indicating the suitability of
dPG derivatives in delivering therapeutic agents systemically.7
In this way, dPG presents an ideal platform for nanomedicine
because it possesses a combination of the following properties:
(a) unique architectural and chemical surface tunability, (b)
signiﬁcantly tolerable surface charge for cell uptake, (c) moderate
aﬃnity and low interactions with plasma proteins, (d) variability
in the size and architecture toward optimization of cellular
internalization and passive accumulation in damage tissues.
5.1 Designing functional architectures based on PG
The linear monohydroxy and terminal dihydroxy functionalities
of dPG scaﬀolds can easily be modiﬁed or functionalized
following classical hydroxyl group chemistry to render a broad
spectrum of products. High loading capacity, water solubility,
and ease of puriﬁcation of the product make dPGs attractive
architectures for carrying out post-polymerization modiﬁcations.
A substantial amount of research has been directed to design
diﬀerent architectures by modiﬁcation of dPG hydroxyl groups
into diﬀerent functionalities. Fig. 16 summarizes diﬀerent group
functionalities that have been used for the further functionalization
of the dPG toward diﬀerent biomedical applications.1
These architectures have already demonstrated their useful-
ness in therapeutic approaches related to multivalency, given
by the synergy between the nanosized dimensions combined
with the high density of functional groups. A challenging
approach to the application of multivalent interactions is the
mimicry of functional biomacromolecules with therapeutic
relevance. Several attempts have been made to mimic speciﬁc
proteins, e.g., histones or polysaccharides like heparin. In
these cases, mimicry is mostly based on the surface charge of
the polymer molecules. In the particular case of dPGs, (1) the
neutral species with hydroxyl end groups represents a good
analog of polysaccharides, (2) polyanionic derivatives present
similar activities to negatively charged polysaccharides,
Fig. 15 Synthetic evolution of dendritic PGs: from dendrons to
megamers. Adapted with permission from ref. 1. Copyright 2010 John
Wiley & Sons, Inc.
Fig. 16 Schematic representation of dPG derivatives used for the
development of functional materials in the ﬁeld of biomedicine. The
depicted polymer structure represents only one possible isomer and a
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e.g., heparin, polysialic acid, and (3) the amine terminated PGs
can act in a similar fashion as histones binding and compact-
ing DNA (Fig. 17). Applications range from protein resistant
coatings (neutral species) to DNA-transfection agents (poly-
cationic systems), anticoagulating and anti-inﬂammatory
drugs (polyanionic systems).1
5.2 Multifunctional PGdrug conjugates for tumor targeting
In a recent communication, we reported the use of the
hyperbranched PG scaﬀold for conjugation to maleimide-
bearing prodrugs of doxorubicin or methotrexate which
incorporate either a self-immolative para-aminobenzyloxy-
carbonyl (PABC) spacer coupled to the dipeptide Phe–Lys or
the tripeptide D-Ala-Phe-Lys as the protease substrate. Both
prodrugs were cleaved by cathepsin B, an enzyme over-expressed
by several solid tumors, to release doxorubicin or a methotrexate
lysine derivative (Fig. 18). Cytotoxicity of the conjugates against
human tumor cell lines showed that the activity of the drugs
was primarily retained, which conﬁrmed the macromolecular
prodrug concept.157
Strategically, thiolated hyperbranched polyglycerols have
been designed to couple either diagnostics or therapeutic
agents. The synthetic protocol consists of four steps. The ﬁrst
three steps for the synthesis of polyglycerolamine with average
molecular weights between 10 and 500 kDa, and up to 20% of
total hydroxyl groups functionalized to amine groups.158
For the synthesis of the thiolated derivatives, three diﬀerent
pathways were studied using 3-(tritylthio)propionic acid,
2-iminothiolane, or acetyl-thiopropionic acid. Among all the
thiolation reactions studied, the 2-iminothiolane pathway was
the most reproducible for the in situ Michael reaction with
maleimide derivatives as the following step.
This modular approach proved to be ﬂexible for coupling
diﬀerent drugs, solubilising agents, as well as imaging and
targeting moieties.17,18 In a recent example we explored this
methodology to prepare PG doxorubicin prodrugs that were
ﬂexible for drug loading by using an acid-sensitive hydrazone
linker and further post-modiﬁcation with poly(ethylene glycol)
shell (Fig. 19). The resulting drug polymer conjugates showed
optimal properties for in vitro and in vivo applications because
of their high water solubility, an appropriate size for passive
tumor toxicity, a high stability at physiological conditions,
pronounced acid-sensitive properties, cellular internalization,
and a favorable toxicity proﬁle. Doxorubicin polyglycerol
conjugates with a high drug loading ratio showed clearly
improved antitumor eﬃcacy over doxorubicin in an ovarian
xenograft tumor model (A2780). This induced transient com-
plete remissions and thus demonstrated its potential for
development of an eﬃcient multifunctional dendritic drug
delivery using our modular approach.159–163
5.3 Applications of polycationic derivatives of PG
Several amine functionalized hyperbranched PGs have been
reported to be potential gene delivery systems after a proper
surface group functionalization.164–169 In comparison to other
dendritic structures, these scaﬀolds have the added advantage
of being open, ﬂexible, and possessing a polyether backbone
which keeps the toxicity proﬁle low. Diﬀerent systems have
been studied by post-modiﬁcation of the hydroxyl groups from
the polyglycerol structure with amine bearing compounds. The
post-modiﬁcation approach for the preparation of hyper-
branched polyglycerols based on core–shell architectures allowed
Fig. 17 Mimicry of biologically active macromolecules. Adapted with permission from ref. 1. Copyright 2010, John Wiley & Sons, Inc.
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an easy control of the transfection/toxicity ratio by tuning the
surface chemistry. It was proved that it is possible, by ﬁne-tuning
the nitrogen containing shell, to obtain better transfection/
toxicity ratios in vitro.169
Our group has recently reported the synthesis of hyper-
branched polyglycerolamine (PG–NH2) with average MW of
10 kDa in an attempt to explore the eﬀects of post-modiﬁcation
of hyperbranched polyglycerol with primary amines in the
favourable 1,2-orientation.169 In a previous study, the poly-
glycerolamine architecture, which consists of primary amine
groups spread all around the polyglycerol structure, has
shown promising properties as a prospective system for gene
delivery, namely because of its high charge with a relative low
cytotoxicity and an optimal charge/pH behavior so far as the
buﬀering capacity is concerned.17 Of all the polyglycerol
systems analyzed for gene transfection,169 the hyperbranched
polyglycerolamine showed the highest aﬃnity towards DNA
fragments, according to an ethidium bromide displacement
assay. The polymer was able to complex siRNA yielding
slightly positive charged globular polyplexes. The knockdown
eﬃciency of the siRNA-polyplex was comparable to HiPer-
Fect for the proteins Lamin, CDC2, and MAPK2 in HeLAS3
cells. In a comparison of silencing eﬃciency and cytotoxicity
with poly(ethylene imine), (PEI) derivatives, the polyglycerol-
amine architecture showed a better toxicity proﬁle at concen-
trations relevant for its activity. It was found that the siRNA
polyplex was internalized into glioblastoma cells within 24
hours by endosome–lysosome mediated system (Fig. 20A).
More interestingly, siRNA–PG–NH2 polyplex was adminis-
tered intratumorally or intravenously to tumor-bearing mice,
resulting in a major silencing eﬀect and no apparent toxicity
(Fig. 20B). High levels of ﬂuorescently labelled siRNA were
detected in the tumor but not in other healthy organs examined,
which probed the passively targeted delivery of siRNA through
EPR eﬀect mediated by the polyglycerolamine species.
More recently, PG–NH2 has been successfully used in
xenografted nude mice to deliver siRNA that down-regulate
the mRNA expression of ferrochelatase (FECH).170 FECH is
an enzyme that is responsible for the last step of the heme-
synthesis, the incorporation of iron into protoporphyrin IX
(PpIX). The in vivo studies demonstrated that siRNA-based
inhibition of FECH results in a blockage of heme-synthesis,
allowing the detection of xenotransplanted human tumor due
to endogenous accumulation of PpIX. The ﬂuorescence imaging
results on animals with xenografted tumors demonstrated that
PG–NH2 improved the local bioavailability of siRNA within the
tumor tissue and facilitate the transfer of siRNA across the cell
membrane.Moreover, siRNA transfected in this way reached the
cytoplasm and was eﬀective in silencing its target FECH as
proven by the high time dependent ﬂuorescence emission of PpIX.
5.4 Applications of negatively charged PG derivatives
Lectins are multivalent carbohydrate-binding proteins which
speciﬁcally bind diﬀerent sugar structures. They have received
considerable attention recently due to their importance in cell
surface interaction and biological recognition. Multivalency in
lectins has been discussed in detail and is considered to be a
good model for studying multivalency of dendritic polymer
derivatives.1 Our group recently explored the use of multivalent
Fig. 19 (A) Schematic representation of the PG doxorubicin prodrugs. (B) Representative release proﬁle of PG-Doxo5-PEG5k incubated at pH 4,
5, 6, and 7 at 37 1C. (C) Curves depicting tumor growth inhibition of subcutaneously growing A2780 xenografts under therapy with doxorubicin
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glycoarchitectures based on PG for the inhibition of L- and
P-selectins, a general class of receptors which displays a selective
adhesion and includes a lectin-like domain.171 Two structures
were compared, namely, free PG-galactose and PG-sulfated
galactose. Selectin inhibition studies carried out with surface
plasmon resonance (SPR) measurements indicated a clearly
enhanced eﬀect due to multivalency. Using L-selectin, the nano-
molar binding aﬃnity of PG-galactose was observed. Notably,
sulfated dendritic galactose showed a further enhancement with
an IC50 of 1 nM. This indicates the importance of negatively
charged sulfate groups on the surface of these polysaccharide
analogs. However, it was speculated that the negative charge of
the sulfate groups alone could be responsible for the strong
interaction with L- and P-selectins.
In an ongoing project by the Haag group, a similar study was
performed using dendritic polyglycerol sulfates (dPGS, Fig. 21),
initially reported as new heparin analogues.172–174 These structures
were found to prolong the time of activated partial thromboplastin
as well as thrombin and to inhibit both the classical and alternative
complement activation more eﬀectively than heparin itself.166,167
The biocompatible and well-tolerated PG sulfate acts as multi-
valent selectin ligand mimetics and eﬃciently blocks leukocyte
migration. L- and P-selectin binding to immobilized ligands was
drastically reduced by the PG sulfates in vitro and gave IC50 values
in the low nanomolar range. The inhibition was strongly dependent
on the core size and degree of sulfation for diﬀerent derivatives.175
Furthermore, only the sulfate groups showed a nanomolar binding
to L-selectines, whereas all other tested polyanions (carboxylates,
sulfonate, phosphonate, phosphate) resulted in a much weaker
binding (B1000 fold).176 In an in vivo model it was observed that
the administration of dendritic PG sulfates in a contact dermatitis
model dampened leukocyte extravasation as eﬀectively as did
Fig. 20 (A) siRNA–PG–amine polyplex intracellular uptake. U87-Luc cells were incubated with TRITC-labeled siRNA (red) either alone
(naked-siRNA) or complexed with PG–amine (siRNA + PG–NH2). Actin ﬁlaments were stained with phalloidin (green). Scale bar represents
25 mm. (B) SCIDmice bearing U87-Luc tumors treated with 10 mg kg1 PG–NH2, complexed with 2.5 mg kg
1 luciferase siRNA (’), 20 mg kg1
PG–NH2, complexed with 5 mg kg
1 luciferase siRNA (m), or saline as control (&). (C) Idealized fragment of polyglycerolamine. Adapted with
permission from ref. 170. Copyright 2010, John Wiley & Sons, Inc.
Fig. 21 (A) Schematic representation of dendritic polyglycerol (dPGS). (B) Comparison of ﬂuorescence images in false colors (normalized to a
ﬂuorescence reference cube) of a control rat and rats with collagen-induced rheumatoid arthritis (diﬀerent clinical scores are indicated) after
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glucocorticoids, and edema formation was signiﬁcantly reduced. In
addition, dPGS interacted with complement factors C3 and C5 as
was shown in vitro and reduced C5a levels in a mouse model of
complement activation.165 In order to investigate whether dPGS
addresses inﬂamed tissue, imaging studies were performed using
dPGS labeled with the near infrared (NIR) dye indocyanine green
(ICG) in an animal model of rheumatoid arthritis. The in vivo
accumulation results demonstrated a fast and selective uptake
which enabled the diﬀerentiation of disease scores and allowed
identiﬁcation of joints with early signs of inﬂammation. Localiza-
tion in tissues using ﬂuorescence histology showed that the con-
jugates are mainly deposited in the inﬂammatory inﬁltrate in the
synovial membrane, whereas non-sulfated control was not detected
in association with disease (Fig. 21).175,177
In conclusion, dendritic polyglycerols are deﬁned 3D archi-
tectures with tunable functionality and inertness to nonspeciﬁc
interactions with biological systems. Therefore PG represents
a novel platform for next generation biomaterials in nano-
medicine. The toxicity proﬁles are well below the limits for
in vivo applications and suited for targeting the disease like
cancer and inﬂammation.
6 Polyglycerol nanogels and their biomedical
applications
Many of the ‘proof of concept’ examples previously described
for dendritic polyglycerol architectures were performed for
particles with sizes between 2 and 15 nm. The continuous need
of new polymeric entities which may be applied in the bio-
medical ﬁeld, calls for careful investigation of dimensional
aspects of polymers, along with their topological features. In
this context, several methodologies have been reported in the
past for the synthesis of PG hydrogels with dimensions in the
micrometre scale.178–180 In order to address diﬀerent length
scales in biology (proteins, viruses, bacteria and cells), multi-
functional micro- and nanogel have been reported by
Haag et al. In the following sections the synthetic methodologies,
as well as the potential applications of such promising polyglycerol
nanogel particles are highlighted.
6.1. Synthetic methodologies
In the pioneer work of Sisson et al. hyperbranched PG
monomers were converted to their high-molecular weight
variant using the nanoreactor template, whereas cross-linking
was achieved by an easy ‘‘click’’ type Huisgen alkyne/azide
cycloaddition reaction.181 It is noteworthy that due to the
conﬁnement of space, no copper was needed for this thermal
[2+3] cycloaddition at only 80 1C. Both hydrophilic and
hydrophobic nanoparticles could therefore be prepared by
the direct and inverse miniemulsion process, yielding nanogels
with particle sizes between 25 and 90 nm.182
More recently, a new concept was developed by our group in
which functional PG nanogels were synthesized by an acid cata-
lyzed polyaddition of glycerol to trisglycidyl glycerol ether utilizing
the inverse miniemulsion technique where the polar reactants were
dispersed in non-polar cyclohexane (Fig. 22).44,183 A poly(ethylene-
co-butylene)-block-poly(ethyleneoxide) surfactant was used as a
stabilizer and a small amount of DMSO was used to prevent
Ostwald ripening. Alternativelly, multifunctional alcohols were
used asmonomers and di- and triepoxides as crosslinking agents.184
The properties of these nanogels, i.e., size, degree of branching,
viscosity, and swelling behavior, could be controlled by varying the
functionalities of the monomers and cross-linkers.
6.2. Polyglycerol nanogels in biomedical applications
Nanogel technology has already established itself as a robust
platform for creation of functional materials with optimal size
and multifunctionality for diﬀerent ﬁelds of applications. The
inherent properties of the polyglycerol gels, related to the high
hydrophilicity, the high biocompatibility, and the controllable
size/architecture in between 20 nm and several micrometres,
enabled their application in several biomedical scenarios. In
particular, the easily functionalizable surface equates to nano-
scale multivalent substrates which could have enhanced
recognition properties toward biological surfaces.185 In addition,
such systems have been postulated for their potential in the ﬁeld
of tissue engineering, since PG gels might biomimic extracellular
matrix (EMC) component proteins.
The interest in PG nanogels spearheads from their non-trivial
synthesis into their biological implications. For example, nano-
gels with sizes between 25 and 350 nm have been shown to
rapidly internalize into the cell, with a preferred localization in
the perinuclear region. As shown in Fig. 23, there is evidence for
a size dependent endocytotic mechanism of cell entry. In addition,
such PG gels architectures aﬀorded a safe cytotoxicity proﬁle in
the mg mL1 range.44,183
For the design of a smart system, biodegradable PG nanogels
and hydrogels were prepared via an acid catalyzed ring-opening
polyaddition of disulﬁde containing polyols and polyepoxides
(Fig. 24).186,187 Varying conditions allowed tuning of the particles
and the disulﬁde content within the polymer network, yielding
particles with narrow polydispersities and diameters in the range
from 25 to 350 nm. Interestingly, the disulﬁde containing
Fig. 22 Synthetic pathways towards pure PG-m-gel and surface
functionalized PG-m-gel particles: (i) cyclohexane/DMSO/block co-
polymer surfactant, sonic tip miniemulsiﬁcation 4  1 min; (ii) p-TSA
(cat.), 115 1C, 16 h; (iii) p-TSA (cat.), 115 1C, varied time; (iv) NaN3,
DMF, 60 1C, 24 h; (v) propargyl derivative, CuSO45H2O, sodium
ascorbate, H2O, 24 h. Adapted with permission from ref. 1. Copyright
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polyglycerol nanogels were found to be highly biocompatible and
to degrade into small oligomeric subunits in reducing environ-
ments. Additionally, a near infrared ﬂuorescent dye was encapsul-
ated in the hydrogel network that showed complete degradation in
reducing media and a controlled release of the ﬂuorescence dye.
Similarly, Groll et al. reported an approach for the preparation
of degradable and biocompatible nanogels from thiol-functional
macromers.188 Linear polyglycerol and star-shaped poly(ethylene
oxide-stat-propylene oxide) were functionalized with thiol groups
by a polymer-analogous reaction and were cross-linked in inverse
miniemulsion conditions. The disulﬁde crosslinked particles
showed to degrade upon addition of aqueous glutathione
solution that resembles cytosolic conditions.
The important role of the nanogel dimension in biological
interactions was recently highlighted in a systematic analysis
of multivalent glycoarchitectures based on PG nanogels in the
inhibition of the inﬂuenza virus.189 In this study, particle sizes
were varied along with the degree of functionalization to
match the corresponding virus size and receptor multiplicity
in order to achieve maximum binding eﬃciency. It was shown
that the inhibitory activities of the polymeric glycoconjugates
drastically increased with the nanoparticle size. Comparing the
inhibition of binding and fusion to inﬂuenza virus, PG
nanogels with 50 nm of diameter was 7  103 folds more
eﬀective than hyperbranched PG with diameter of 3 nm at
comparable sugar concentrations. Moreover, it was demon-
strated that the nanogel reduced viral activity by up to 80%.
This emphasizes the importance of matching sizes and multi-
plicity for biological surface interactions, which is achieved by the
particles dimensionality of the PG nanogels (Fig. 25).
The fabrication of thermo-responsive PG nanogels was recently
developed by Caldero´n et al., in an attempt to develop stimuli-
responsive materials based on dendritic polyglycerols.190 In this
work, a precipitation polymerizationmethodwas used to cross-link
N-isopropylacrylamide (NIPAm) and hyperbranched PG to yield
nanogels with sizes between 50 and 200 nm. The incorporation of
PG as crosslinking agent enhanced the water solubility of the
nanogels, improved their biocompatible proﬁle, and allowed a ﬁne
tuning of the thermo-responsive proﬁle regarding the size of the
nanogels in solutions (Fig. 26).
7 Opportunities
Nanotechnology revolves around the design and control of
materials at length scales between 1–1000 nm which implicates
its usefulness for applications in nanomedicine. In the next 10–15
years, many specialized medical applications on the nanoscale
will arise especially in the areas of pharmaceutical products, drug
delivery systems, and health-monitoring devices.191 The need to
design and evaluate new polymeric biomaterials for individual
biological applications is larger than ever. Recently, a variety of
new macromolecular architectures have been synthesized based
on properties and functions of delivery components. In addition,
such nanotherapeutics must reduce accumulation in normal
tissues, thereby decreasing drug related adverse side eﬀects.
Furthermore, the polymer and its bioconjugate should enhance
the aqueous solubility and stability of the bioactives.
One of the key challenges in creating an eﬀective and safer
nanoplatform is to achieve targetability to the appropriate
tissues and cells. Although biological targeting using aptamers
or antibodies on the surface of nanoparticles is one popular
option, researchers are beginning to explore the physical
characteristics of the nanoforms to guide them to desired
locations. The size, shape, physical properties, density, and
charge all aﬀect how nanomedicines will travel through the
body, and whether or not they will cross biological membranes.
Enormous eﬀorts have been made to combine pH and tempera-
ture responsive modalities in nanocarriers to develop a smart
delivery system based on dendritic polyglycerols.1 The resulting
nanosystems have many biomedical applications, since the
Fig. 23 Fluorescence microscopy shows clear evidence for cellular uptake of ﬂuorescently labeled PG microgels via an endocytotic pathway.
Adapted with permission from ref. 1. Copyright 2010 John Wiley & Sons, Inc.
Fig. 24 Synthetic route to biodegradable polyglycerol nanogels, showing
a generalized depiction of a nanogel and degradation fragment. Adapted
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temperature and pH of the target sites could be modulating
factors for triggering activity of biomolecules.
The choice of appropriate nanocarriers is not obvious, and
comparative studies are diﬃcult to interpret because many
factors simultaneously aﬀect the biocompatibility, biodistribution,
and targeting. However, the improved therapeutic eﬃcacy of
targeted nanocarriers has been established in multiple animal
models of cancer, and currently more than 120 clinical trials are
underway with various combinations of nanoformulations.192
And yet, many challenges still remain such as the synthesis of a
highly biocompatible, biodegradable, intelligent releasing nano-
carrier system which can be cleared up by kidneys, to achieve the
desired biological availability and biodistribution.
8 Conclusions
Nanomedicine is driven by the success in the creation of
innovative and safe ‘nanosize materials’ through the control
of synthesis on the nanometre scale. The deﬁnable architec-
tures, synthetic tunability, and chemical versatility of nano-
carriers have increased the perspectives in the ﬁeld of
nanotherapeutics and nanodiagnostics. Also, they have created
a new ﬁeld of therapeutics by combining both modalities. The
inherent nanoscale functions of dendritic polymers seem to be
inevitable in numerous applications in life sciences and oﬀer
extraordinary, paradigm-changing opportunities with signiﬁcant
advances in cancer diagnosis and treatments. Especially, muli-
functional PEG-like polymers, such as dendritic polyglycerols,
provide a new platform for bridging the gap between molecular
sciences, functional materials, and polymer therapeutics. Poly-
glycerols can be produced by straightforward syntheses, various
architectures ranging from perfect dendrons to well-deﬁned
hyperbranched polymers, micro and nanogels, and multicompo-
nent nanoconjugates. Although some ﬁrst promising results are
available for dendritic polyglycerols, maximized biocompatibility
on the cellular and systemic levels, metabolism, PKPD proﬁle,
and maximum tolerated dose of speciﬁc drug conjugates still
need to be studied in greater detail. Nanomedicines derived from
dendritic polymers already play an important role in the treatment
of cancer and inﬂammation in two broad areas: the development
of nanovectors, such as nanodepots and nanoconjugates, with
drugs or imaging agents and for targeting the tumors and
inﬂammation sites. Combined, such technologies could lead to
an earlier diagnosis and better treatment of patients with chronic
inﬂammation and cancer. The prime focus is now initiated in
designing more versatile biomaterials to be implied in nano-
medicines, considering biophysicochemical interactions at the
nano–bio interface. More importantly, nanomedicines have to
pass through very stringent regulations and approval protocols
before entering into phase I clinical trials, thereby delaying overall
timelines.
Conclusively, the design of polymeric architectures, their
structure–activity relationship and translation into multicom-
ponent nanosystems for biological applications and target-
ability is still in its infancy. The controlled synthesis under
GMP-like protocols and vigorous biological evaluation of
Fig. 25 Schematic representation of sialic acid-conjugated PG-based nanoparticles that match inﬂuenza virus size and receptor multiplicity.
Adapted with permission from ref. 189. Copyright 2011, John Wiley & Sons, Inc.
Fig. 26 Thermo-responsive polyglycerol based nanogels synthesized
through precipitation polymerization. The nanogels showed a tendency
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polymeric nanocarriers are absolutely necessary for the trans-
lation of nanomedicines from laboratory into the clinic.
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